← REGENERON PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4.9b | $5.9b | $6.7b | $7.9b | $8.5b | $16.1b | $12.2b | $13.1b | $14.2b | $14.3b | |
| Cost of Goods and Services Sold | $194.6m | $202.5m | $434.1m | $782.2m | $1.1b | $5.3b | $1.6b | $1.8b | $2.0b | $8.1b | |
| Gross Profit (Calculated) (derived) | $4.7b | $5.7b | $6.3b | $7.1b | $7.4b | $10.8b | $10.6b | $11.3b | $12.2b | $6.3b | |
| Operating expenses: | |||||||||||
| Operating Income (Loss) | $1.3b | $2.1b | $2.5b | $2.2b | $3.6b | $8.9b | $4.7b | $4.0b | $4.0b | $3.6b | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | — | — | — | — | — | — | — | $92.2m | $128.9m | $178.8m | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | — | — | — | — | — | $966.2m | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | — | — | — | $29.0m | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | $2.0b | $2.4b | $5.9b | $839.9m | ($362.3m) | ($411.3m) | ($476.3m) | |
| Interest Income, Debt Securities, Operating | — | — | — | — | — | — | $160.1m | $495.9m | $711.4m | $716.8m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | $9.3b | $4.9b | $4.2b | $4.8b | $5.2b | |
| Net Income (Loss) Attributable to Parent | $895.5m | $1.2b | $2.4b | $2.1b | $3.5b | $8.1b | $4.3b | $4.0b | $4.4b | $4.5b | |
| Earnings Per Share, Basic | $8.55 | $11.27 | $22.65 | $19.38 | $32.65 | $76.40 | $40.51 | $37.05 | $40.90 | $43.07 | |
| Earnings Per Share, Diluted | $7.70 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | |
| Weighted Average Number of Shares Outstanding, Basic | 104.7m | 106.3m | 107.9m | 109.2m | 107.6m | 105.7m | 107.1m | 106.7m | 107.9m | 104.6m | |
| Weighted Average Number of Shares Outstanding, Diluted | 116.4m | 116.0m | 114.8m | 114.6m | 115.1m | 112.2m | 113.5m | 113.7m | 115.1m | 108.6m | |
| Research and Development Expense | $2.1b | $2.1b | $2.2b | $3.0b | $2.7b | $2.9b | $3.6b | $4.4b | $5.1b | $5.9b | |
| Selling, General and Administrative Expense | $1.2b | $1.3b | $1.6b | $1.8b | $1.3b | $1.8b | $2.1b | $2.6b | $3.0b | $2.7b | |
| Other Nonoperating Income (Expense) | $6.3m | $24.0m | $47.3m | $249.5m | $290.7m | $436.3m | $179.3m | $225.2m | $844.4m | $1.7b | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $55.2m | $43.8m | |
| Costs and Expenses | $3.5b | $3.8b | $4.2b | $5.7b | $4.9b | $7.1b | $7.4b | $9.1b | $10.2b | $10.8b | |
| Current Income Tax Expense (Benefit) | $794.4m | $561.0m | $249.1m | $443.9m | $221.6m | $1.4b | $1.3b | $1.1b | $1.1b | $1.5b | |
| Interest Expense | $7.2m | $25.1m | $28.2m | $30.2m | $56.9m | $57.3m | $59.4m | $73.0m | $55.2m | $43.8m | |
| Income Tax Expense (Benefit) | $434.3m | $880.0m | $109.1m | $313.3m | $297.2m | $1.3b | $520.4m | $245.7m | $367.3m | $725.8m | |
| Interest Income (Expense), Nonoperating, Net | ($7.2m) | ($25.1m) | — | — | — | — | — | — | — | — | |
| Other Operating Income (Expense), Net | $1.3b | $2.1b | $2.5b | $2.2b | $280.4m | $45.6m | $89.9m | $2.1m | ($53.4m) | $10.0m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.